Patents by Inventor Eleni Markoutsa

Eleni Markoutsa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11951152
    Abstract: This disclosure is directed to therapeutic compositions, and more particularly to microparticle compositions for the controlled delivery of telmisartan and actinomycin D.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: April 9, 2024
    Assignees: University of South Florida, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS
    Inventors: Subhra Mohapatra, Shyam S. Mohapatra, Eleni Markoutsa, Alejandro J. Gonzalez, Heta N. Jadhav
  • Publication number: 20240100047
    Abstract: A nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a single or a combination of therapeutic agents, optionally encapsulated in a nanoparticle having a targeting moiety directed to the particular coronavirus. For CoV-2 infections, at least one therapeutic agent, such as the dual DPP4/ACE2 inhibitor sitagliptin, may optionally be encapsulated within a nanoparticle having a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.
    Type: Application
    Filed: November 14, 2023
    Publication date: March 28, 2024
    Inventors: Subhra Mohapatra, Shyam S. Mohapatra, Karthick Mayilsamy, Eleni Markoutsa, Andrew McGill
  • Publication number: 20240065983
    Abstract: A multi-functional broad-spectrum antiviral and anti-inflammatory nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a combination of therapeutic agents directed to the particular coronavirus encapsulated in a nanoparticle that is surface coated with a targeting moiety. For CoV-2 infections, an antiviral such as the PPAR-? agonist leriglitazone (LG) and an siRNA targeting a conserved sequence of the virus can be encapsulated within a nanoparticle surface coated with a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.
    Type: Application
    Filed: October 27, 2023
    Publication date: February 29, 2024
    Inventors: Subhra Mohapatra, Shyam S. Mohapatra, Karthick Mayilsamy, Eleni Markoutsa, Andrew McGill
  • Patent number: 11911481
    Abstract: This invention provides for a RSV-targeted nanoparticle PMN (RTPMN), combining HR2D anti-fusion peptide, and plasmid encoded siRNA against RSV-NS1 and/or RSV-P gene as a safe, effective and inexpensive anti-RSV prophylaxis and/or therapy.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: February 27, 2024
    Assignees: UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, UNIVERSITY OF SOUTH FLORIDA
    Inventors: Eleni Markoutsa, Subhra Mohapatra, Shyam Mohapatra
  • Publication number: 20240033240
    Abstract: The preparation of dual functionalized nanoparticles is generally provided along with their application. The dual functionalized nanoparticles provide dual targeting and can effectively pass the blood brain barrier and target brain tissue. The dual targeted and dual responsive nanoparticles are functionalized to include at least two different ligands that are capable of transport across the blood brain barrier. The nanoparticles can be prepared from polymeric materials that can be biocompatible, provide long circulation life in a body, and be successfully ligated to both functionalities by use of acid-sensitive and/or redox potential-sensitive bonds for delivery across the blood brain barrier and delivery of a payload to brain tissue.
    Type: Application
    Filed: October 2, 2023
    Publication date: February 1, 2024
    Inventors: Peisheng Xu, Eleni Markoutsa
  • Patent number: 11752220
    Abstract: A multifunctional dendrimer nanoparticle and method of treating diseases of the posterior segment of the eye is presented. The functionalized polyamidoamine (PAMAM) dendrimer effectively delivers drugs and/or genes to the posterior eye, thereby providing for the effective, non-invasive, and topical treatment of diseased in the posterior eye. The multifunctional dendrimer nanoparticle has shRNA-encoding DNA and small molecule drug encapsulated cyclodextrin complexed to the outer surface of the dendrimer for delivery to the posterior segment of the eye.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: September 12, 2023
    Assignees: The United States Government as Represented by the Department of Veterans Affair, University of South Florida
    Inventors: Shyam S. Mohapatra, Subhra Mohapatra, Eleni Markoutsa
  • Publication number: 20220395477
    Abstract: The present disclosure relates to compositions and uses thereof for preventing and treating respiratory syncytial vims (RSV) infection. In some aspects, disclosed herein is a method for preventing or treating respiratory syncytial vims (RSV) infection in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a short-chain fatty acid.
    Type: Application
    Filed: October 29, 2020
    Publication date: December 15, 2022
    Inventors: Shyam S. MOHAPATRA, Subhra MOHAPATRA, Andrew Robert MCGILL, Eleni MARKOUTSA
  • Publication number: 20220062382
    Abstract: Compositions and methods for treating traumatic brain injury (TBI) are presented. Novel dendriplexes are formed from poly(amidoamine) (PAMAM) dendrimers complexed with shRNA encoding DNA plasmids encapsulating shRNA encoding chemokine ligand 20 (CCL20) gene, chemokine receptor 6 (CCR6) gene, or a combination thereof. The dendriplexes are dually administered, both intranasally and intravenously, prior to administration of stem cells, such as human mesenchymal stem cells (hMSCs) for the treatment of traumatic brain injury (TBI). Administration of the dendriplexes prior to stem cell administration resulted in a decrease in neurodegeneration, neuroinflammation, microgliosis and astrogliosis. In addition, a synergistic increase in brain derived trophic factor (BDNF) was shown by administration of the combination of dendriplex and stem cell administration.
    Type: Application
    Filed: November 10, 2021
    Publication date: March 3, 2022
    Inventors: Subhra Mohapatra, Shyam S. Mohapatra, Karthick Mayilsamy, Eleni Markoutsa
  • Publication number: 20210253422
    Abstract: This invention provides for a RSV-targeted nanoparticle PMN (RTPMN), combining HR2D anti-fusion peptide, and plasmid encoded siRNA against RSV-NS1 and/or RSV-P gene as a safe, effective and inexpensive anti-RSV prophylaxis and/or therapy.
    Type: Application
    Filed: May 21, 2019
    Publication date: August 19, 2021
    Inventors: Eleni Markoutsa, Subhra Mohapatra, Shyam Mohapatra
  • Publication number: 20160346208
    Abstract: The preparation of dual functionalized nanoparticles is generally provided along with their application. The dual functionalized nanoparticles provide dual targeting and can effectively pass the blood brain barrier and target brain tissue. The dual targeted and dual responsive nanoparticles are functionalized to include at least two different ligands that are capable of transport across the blood brain barrier. The nanoparticles can be prepared from polymeric materials that can be biocompatible, provide long circulation life in a body, and be successfully ligated to both functionalities by use of acid-sensitive and/or redox potential-sensitive bonds for delivery across the blood brain barrier and delivery of a payload to brain tissue.
    Type: Application
    Filed: May 26, 2016
    Publication date: December 1, 2016
    Inventors: Peisheng Xu, Eleni Markoutsa